Can fluvoxamine cause somnolence?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Fluvoxamine Cause Drowsiness?

Yes, fluvoxamine can cause somnolence (drowsiness), though it can also paradoxically cause insomnia in some patients.

Key Evidence on Somnolence

According to FDA labeling data, somnolence occurred in 22% of patients taking fluvoxamine compared to 8% on placebo in controlled trials 1. This represents a nearly 3-fold increased risk. Notably, somnolence was common enough that 4% of patients discontinued fluvoxamine specifically due to somnolence 1.

In a large postmarketing safety database of 24,624 patients, somnolence occurred in 6.9% of patients, making it the second most common adverse effect after nausea 2. Among SSRIs specifically, fluvoxamine ranked highest for causing somnolence with an odds ratio of 6.32 compared to placebo 3.

The Paradox: Insomnia vs. Somnolence

Fluvoxamine exhibits a bidirectional effect on sleep:

  • Insomnia also occurs frequently, affecting 21% of patients versus 10% on placebo 1
  • This dual effect is characteristic of SSRIs as a class, which can cause "insomnia or somnolence" 4
  • The specific effect experienced appears to vary by individual patient factors

Clinical Implications

When counseling patients:

  • Warn them that drowsiness is a common side effect occurring in approximately 1 in 5 patients
  • Explain that the opposite effect (insomnia) can also occur
  • Advise caution with activities requiring alertness (driving, operating machinery) until they know how the medication affects them
  • Consider timing of dosing: the drug can be given at bedtime if somnolence predominates, or in the morning if insomnia is the issue 5

Important drug interaction: Fluvoxamine clearance is significantly reduced when combined with ciprofloxacin, which can increase sedation risk 6.

Overdose Considerations

In overdose situations, somnolence is one of the most common presenting symptoms (≥5% of cases), along with coma in severe cases 1. This underscores the drug's sedating potential at higher concentrations.

Related Questions

I have been taking Prozac (fluoxetine) 20 mg and Vyvanse (lisdexamfetamine) 30 mg for two months; they were effective but now I am having difficulty falling asleep. What should I do?
Can fluvoxamine (Luvox) cause hypersomnia, characterized by prolonged sleep duration of 11-13 hours?
After taking Prozac (fluoxetine) for about a month, I'm experiencing alternating insomnia and excessive sleepiness; is this a normal early side effect and how can I manage it?
In a 62‑year‑old patient taking venlafaxine XR (Effexor) 112.5 mg for depression and anxiety who now reports insomnia, vivid dreams, racing thoughts during conversation, and decreased motivation, how should his symptoms be managed?
How can I manage excessive sleepiness in a patient taking Abilify (aripiprazole)?
What is the recommended dilution and dosage of pemetrexed (500 mg/m²) for intravenous infusion, including preparation, infusion volume, and renal dose adjustments?
I am taking levothyroxine 150 µg daily and atorvastatin 10 mg; my recent labs show suppressed thyroid‑stimulating hormone (TSH) at 0.07 uIU/mL, normal free triiodothyronine (free T3), elevated free thyroxine (free T4) at 1.80 ng/dL, and a lipid panel with calculated low‑density lipoprotein (LDL) 62 mg/dL, triglycerides 40 mg/dL, high‑density lipoprotein (HDL) 58 mg/dL, and cholesterol/HDL ratio 2.2. What adjustments should I make to my levothyroxine dose and lipid management?
In a patient with proximal ascending aorta dilation measuring 4.3 cm (indexed 2.3 cm/m²) on echocardiography and 4.4 cm on magnetic resonance imaging, what is the next best step in management?
Who is eligible to receive Tamiflu (oseltamivir) for treatment or prophylaxis?
In a diabetic patient with an incidental unilateral 70% carotid artery stenosis and LDL cholesterol of 210 mg/dL (total cholesterol 290 mg/dL), should we prescribe atorvastatin, apixaban, or a sodium‑glucose cotransporter‑2 (SGLT2) inhibitor?
For a patient undergoing total knee arthroplasty with a prior gastrointestinal bleed, which anticoagulant regimen and prophylaxis strategy is recommended?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.